Claims for Patent: 11,884,696

Summary for Patent: 11,884,696

Title:	Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid
Abstract:	This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
Inventor(s):	Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
Assignee:	Sage Therapeutics Inc
Application Number:	US17/396,464
Patent Claims:	1. A method for treating a CNS-related disorder, wherein the CNS-related disorder is a mood disorder, a psychotic disorder, an anxiety disorder, tremor, or tinnitus, in a subject in need thereof, comprising administering to the subject an effective amount of a crystalline solid Form C of Compound 1: wherein the crystalline solid Form C of Compound 1 has an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 11.6 to 12.0 degrees in 2θ, between and including 13.2 to 13.6 degrees in 2θ, between and including 14.2 to 14.6 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, between and including 21.3 to 21.7 degrees in 2θ, between and including 21.4 to 21.8 degrees in 2θ, and between and including 22.4 to 22.8 degrees in 2θ. 2. The method of claim 1, wherein the peak between and including 9.7 to 10.1 is 9.9 degrees in 2θ, the peak between and including 11.6 to 12.0 is 11.8 degrees in 2θ, the peak between and including 13.2 to 13.6 is 13.4 degrees in 2θ, the peak between and including 14.2 to 14.6 is 14.4 degrees in 2θ, the peak between and including 14.6 to 15.0 degrees is 14.8 in 2θ, the peak between and including 16.8 to 17.2 is 17.0 degrees in 2θ, the peak between and including 20.5 to 20.9 is 20.7 degrees in 2θ, the peak between and including 21.3 to 21.7 is 21.5 degrees in 2θ, the peak between and including 21.4 to 21.8 is 21.6 degrees in 2θ, and the peak between and including 22.4 to 22.8 is 22.6 degrees in 2θ. 3. The method of claim 1, wherein the mood disorder is treatment-resistant depression. 4. The method of claim 1, wherein the mood disorder is a major depressive disorder (MDD). 5. The method of claim 1, wherein the mood disorder is postpartum depression (PPD) or perinatal depression. 6. The method of claim 1, wherein the anxiety disorder is a generalized anxiety disorder. 7. The method of claim 1, wherein the tremor is essential tremor. 8. The method of claim 1, wherein the psychotic disorder is bipolar disorder. 9. The method of claim 1, wherein the crystalline solid Form C of Compound 1 is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, as a buccal, sublingually, rectally, as a topical, as an inhalation, intranasally, or transdermally. 10. A method for treating a CNS-related disorder, wherein the CNS-related disorder is a mood disorder, a psychotic disorder, an anxiety disorder, tremor, or tinnitus, in a subject in need thereof, comprising administering to the subject an effective amount of a crystalline solid Form C of Compound 1: wherein the crystalline solid Form C of Compound 1 has an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, and between and including 21.3 to 21.7 degrees in 2θ. 11. The method of claim 10, wherein the tremor is essential tremor. 12. The method of claim 10, wherein the psychotic disorder is bipolar disorder. 13. The method of claim 10, wherein the crystalline solid Form C of Compound 1 is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, as a buccal, sublingually, rectally, as a topical, as an inhalation, intranasally, or transdermally. 14. The method of claim 13, wherein the crystalline solid Form C of Compound 1 is administered orally. 15. A method for treating a CNS-related disorder, wherein the CNS-related disorder is a mood disorder, a psychotic disorder, an anxiety disorder, tremor, or tinnitus, in a subject in need thereof, comprising administering to the subject an effective amount of a crystalline solid Form C of Compound 1: wherein the crystalline solid Form C of Compound 1 has an XRPD pattern comprising peaks at 9.9 degrees in 2θ, 14.8 degrees in 2θ, 17.0 degrees in 2θ, 20.7 degrees in 2θ, and 21.5 degrees in 2θ. 16. The method of claim 15, wherein the tremor is essential tremor. 17. The method of claim 15, wherein the psychotic disorder is bipolar disorder. 18. The method of claim 15, wherein the crystalline solid Form C of Compound 1 is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, as a buccal, sublingually, rectally, as a topical, as an inhalation, intranasally, or transdermally. 19. The method of claim 18, wherein the crystalline solid Form C of Compound 1 is administered orally.